SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-
How this was made
The 30-second read
Why it matters
Quarterly results show rapid adoption and new Medicaid coverage, potentially expanding the addressable market to ~7 million patients.
Market read
First‑report earnings with strong growth metrics; likely to move the stock and influence peers in the prenatal‑diagnostics space.
What to watch
The $0.4 M severance expense hints at restructuring; cash burn of $7.3 M may require additional financing later.
Background
Sera Prognostics (Nasdaq: SERA) is a diagnostics company targeting preterm‑birth risk with its PreTRM test.
Ticker impact
Sera Prognostics filed its Form 8‑K reporting Q3 2026 results, revealing a 163% YoY revenue increase and new Medicaid coverage in Florida and Illinois.
likely upward pressure as investors price in higher test volumes and new Medicaid reimbursements
Quarterly earnings are a primary disclosure; the company showed significant revenue growth, new state coverage, and a cash position of $72.8 M, all fresh information.
Market effects
May boost sentiment for prenatal‑care diagnostics and other biotech firms with Medicaid reimbursement pathways.
Positive for U.S. healthcare stocks, especially those with state Medicaid contracts.
Limited; primarily U.S. focused but could attract European interest as CE‑Mark submission begins.
Counterpoint
Revenue growth is offset by lower average selling prices and higher mix of non‑reimbursed tests, which could pressure margins.
Key entities
- ExecutiveZhenya Lindgardt
President and CEO of Sera Prognostics, quoted on the earnings release.
